Summary
patients treated

Has anyone ever benefited from stem cell?

For the first time, umbilical cord blood cells were successfully used in 1988 in France. Several years later, in 2007, this method was also introduced by FamiCord Group in Poland. So far, umbilical cord blood stem cells have been transplanted over 40,000 times worldwide, saving peoples’ lives and health.

FamiCord Group enables their clients innovative treatment with stem cells. Check the full list of patients, suffered from diverse disorders, who benefited from it.

List of patients

List of patients
No.	Source	Source type	Diagnosis	Medical sector	Year of application	Therapy	Country	Age of the recipient
1401	Apheresis	Allogeneic	Chronic Myelogenous Leukemia	Hematology	2022	Standard Therapy	Poland	59
1402	Apheresis	Allogeneic	Chronic Myelogenous Leukemia	Hematology	2022	Standard Therapy	Poland	64
1403	Apheresis	Allogeneic	Chronic Myelogenous Leukemia	Hematology	2022	Standard Therapy	Poland	60
1404	Apheresis	Allogeneic	Chronic Myelomonocytic Leukemia	Hematology	2022	Standard Therapy	Poland	70
1405	Apheresis	Allogeneic	Chronic Myelomonocytic Leukemia	Hematology	2022	Standard Therapy	Poland	54
1406	Apheresis	Allogeneic	Chronic Myelomonocytic Leukemia	Hematology	2022	Standard Therapy	Poland	63
1407	Apheresis	Allogeneic	Chronic Myelomonocytic Leukemia	Hematology	2022	Standard Therapy	Poland	54
1408	Apheresis	Allogeneic	Chronic Myelomonocytic Leukemia	Hematology	2022	Standard Therapy	Poland	71
1409	Apheresis	Allogeneic	Chronic Myelomonocytic Leukemia	Hematology	2022	Standard Therapy	Poland	67
1410	Apheresis	Allogeneic	Chronic Myelomonocytic Leukemia, Type 0 (Cmml-0)	Hematology	2022	Standard Therapy	Poland	64
1411	Apheresis	Allogeneic	Chronic Neutrophilic Leukemia	Hematology	2022	Standard Therapy	Poland	66
1412	Apheresis	Allogeneic	Chronic Neutrophilic Leukemia	Hematology	2022	Standard Therapy	Poland	72
1413	Apheresis	Allogeneic	Combined Immunodeficiency Syndrome With Hyper-Igm	Hematology	2022	Standard Therapy	Poland	6
1414	Apheresis	Allogeneic	Congenital Dyserythropoietic Anemia	Hematology	2022	Standard Therapy	Poland	2
1415	Apheresis	Autologous	Diffuse Large B-Cell Lymphoma	Hematology	2022	Standard Therapy	Germany	68
1416	Apheresis	Autologous	Diffuse Large B-Cell Lymphoma	Hematology	2022	Standard Therapy	Germany	65
1417	Apheresis	Autologous	Diffuse Large B-Cell Lymphoma	Hematology	2022	Standard Therapy	Germany	69
1418	Apheresis	Autologous	Diffuse Large B-Cell Lymphoma	Hematology	2022	Standard Therapy	Germany	50
1419	Apheresis	Autologous	Diffuse Large B-Cell Lymphoma	Hematology	2022	Standard Therapy	Germany	56
1420	Apheresis	Autologous	Diffuse Large B-Cell Lymphoma	Hematology	2022	Standard Therapy	Germany	65
1421	Apheresis	Autologous	Diffuse Large B-Cell Lymphoma	Hematology	2022	Standard Therapy	Germany	47
1422	Apheresis	Autologous	Diffuse Large B-Cell Lymphoma – Relapse	Hematology	2022	Standard Therapy	Germany	66
1423	Apheresis	Autologous	Diffuse Large B-Cell Lymphoma With Cerebral Acute Lymphoblastic Leukemia	Hematology	2022	Standard Therapy	Germany	66
1424	Apheresis	Autologous	Germ Cell Tumor	Hematology	2022	Standard Therapy	Germany	39
1425	Apheresis	Autologous	Germ Cell Tumor	Hematology	2022	Standard Therapy	Germany	33
1426	Apheresis	Allogeneic	Hemophagocytic Lymphohistiocytosis (Hlh)	Hematology	2022	Standard Therapy	Poland	12
1427	Apheresis	Allogeneic	Hemophagocytic Lymphohistiocytosis (Hlh)	Hematology	2022	Standard Therapy	Poland	21
1428	Apheresis	Allogeneic	Hodgkin Lymphoma	Hematology	2022	Standard Therapy	Poland	26
1429	Apheresis	Allogeneic	Hodgkin Lymphoma	Hematology	2022	Standard Therapy	Poland	31
1430	Apheresis	Allogeneic	Hodgkin Lymphoma	Hematology	2022	Standard Therapy	Poland	53
1431	Apheresis	Allogeneic	Hodgkin Lymphoma	Hematology	2022	Standard Therapy	Poland	25
1432	Apheresis	Autologous	Hodgkin Lymphoma	Hematology	2022	Standard Therapy	Germany	67
1433	Apheresis	Autologous	Hodgkin Lymphoma-Relapse	Hematology	2022	Standard Therapy	Germany	69
1434	Apheresis	Autologous	Hodgkin Lymphoma-Relapse	Hematology	2022	Standard Therapy	Germany	48
1435	Apheresis	Allogeneic	Hypoplastic Myelodysplastic Syndrome	Hematology	2022	Standard Therapy	Poland	26
1436	Apheresis	Allogeneic	Immunodeficiency	Hematology	2022	Standard Therapy	Poland	3
1437	Apheresis	Allogeneic	Juvenile Myelomonocytic Leukemia	Hematology	2022	Standard Therapy	Poland	5
1438	Apheresis	Autologous	Mantle Cell Lymphoma	Hematology	2022	Standard Therapy	Germany	64
1439	Apheresis	Autologous	Mantle Cell Lymphoma	Hematology	2022	Standard Therapy	Germany	61
1440	Apheresis	Autologous	Mantle Cell Lymphoma	Hematology	2022	Standard Therapy	Germany	52
1441	Apheresis	Autologous	Mantle Cell Lymphoma	Hematology	2022	Standard Therapy	Germany	44
1442	Apheresis	Autologous	Mantle Cell Lymphoma	Hematology	2022	Standard Therapy	Germany	53
1443	Apheresis	Autologous	Mantle Cell Lymphoma	Hematology	2022	Standard Therapy	Germany	49
1444	Apheresis	Autologous	Mantle Cell Lymphoma	Hematology	2022	Standard Therapy	Germany	64
1445	Apheresis	Allogeneic	Mixed Phenotype Acute Leukemia	Hematology	2022	Standard Therapy	Poland	64
1446	Apheresis	Autologous	Morbus Hodgkin	Hematology	2022	Standard Therapy	Germany	36
1447	Apheresis	Autologous	Morbus Hodgkin	Hematology	2022	Standard Therapy	Germany	62
1448	Apheresis	Autologous	Morbus Hodgkin-Relapse	Hematology	2022	Standard Therapy	Germany	63
1449	Apheresis	Allogeneic	Mucopolysaccharidosis	Hematology	2022	Standard Therapy	Poland	2
1450	Apheresis	Allogeneic	Mucopolysaccharidosis Type I	Hematology	2022	Standard Therapy	Poland	3
1451	Apheresis	Autologous	Multiple Myeloma	Hematology	2022	Standard Therapy	Germany	58
1452	Apheresis	Autologous	Multiple Myeloma	Hematology	2022	Standard Therapy	Germany	53
1453	Apheresis	Autologous	Multiple Myeloma	Hematology	2022	Standard Therapy	Germany	57
1454	Apheresis	Autologous	Multiple Myeloma	Hematology	2022	Standard Therapy	Germany	64
1455	Apheresis	Autologous	Multiple Myeloma	Hematology	2022	Standard Therapy	Germany	50
1456	Apheresis	Autologous	Multiple Myeloma	Hematology	2022	Standard Therapy	Germany	67
1457	Apheresis	Autologous	Multiple Myeloma	Hematology	2022	Standard Therapy	Germany	55
1458	Apheresis	Autologous	Multiple Myeloma	Hematology	2022	Standard Therapy	Germany	73
1459	Apheresis	Autologous	Multiple Myeloma	Hematology	2022	Standard Therapy	Germany	63
1460	Apheresis	Autologous	Multiple Myeloma	Hematology	2022	Standard Therapy	Germany	65
1461	Apheresis	Autologous	Multiple Myeloma	Hematology	2022	Standard Therapy	Germany	58
1462	Apheresis	Autologous	Multiple Myeloma	Hematology	2022	Standard Therapy	Germany	37
1463	Apheresis	Autologous	Multiple Myeloma	Hematology	2022	Standard Therapy	Germany	47
1464	Apheresis	Autologous	Multiple Myeloma	Hematology	2022	Standard Therapy	Germany	68
1465	Apheresis	Autologous	Multiple Myeloma	Hematology	2022	Standard Therapy	Germany	53
1466	Apheresis	Autologous	Multiple Myeloma	Hematology	2022	Standard Therapy	Germany	60
1467	Apheresis	Autologous	Multiple Myeloma	Hematology	2022	Standard Therapy	Germany	60
1468	Apheresis	Autologous	Multiple Myeloma	Hematology	2022	Standard Therapy	Germany	47
1469	Apheresis	Autologous	Multiple Myeloma	Hematology	2022	Standard Therapy	Germany	59
1470	Apheresis	Autologous	Multiple Myeloma	Hematology	2022	Standard Therapy	Germany	64
1471	Apheresis	Autologous	Multiple Myeloma	Hematology	2022	Standard Therapy	Germany	59
1472	Apheresis	Autologous	Multiple Myeloma	Hematology	2022	Standard Therapy	Germany	52
1473	Apheresis	Autologous	Multiple Myeloma	Hematology	2022	Standard Therapy	Germany	73
1474	Apheresis	Autologous	Multiple Myeloma	Hematology	2022	Standard Therapy	Germany	68
1475	Apheresis	Autologous	Multiple Myeloma	Hematology	2022	Standard Therapy	Germany	63
1476	Apheresis	Autologous	Multiple Myeloma	Hematology	2022	Standard Therapy	Germany	66
1477	Apheresis	Autologous	Multiple Myeloma	Hematology	2022	Standard Therapy	Germany	50
1478	Apheresis	Autologous	Multiple Myeloma	Hematology	2022	Standard Therapy	Germany	69
1479	Apheresis	Autologous	Multiple Myeloma	Hematology	2022	Standard Therapy	Germany	57
1480	Apheresis	Autologous	Multiple Myeloma	Hematology	2022	Standard Therapy	Germany	55
1481	Apheresis	Autologous	Multiple Myeloma	Hematology	2022	Standard Therapy	Germany	61
1482	Apheresis	Autologous	Multiple Myeloma	Hematology	2022	Standard Therapy	Germany	64
1483	Apheresis	Autologous	Multiple Myeloma	Hematology	2022	Standard Therapy	Germany	71
1484	Apheresis	Autologous	Multiple Myeloma	Hematology	2022	Standard Therapy	Germany	61
1485	Apheresis	Autologous	Multiple Myeloma	Hematology	2022	Standard Therapy	Germany	62
1486	Apheresis	Autologous	Multiple Myeloma	Hematology	2022	Standard Therapy	Germany	60
1487	Apheresis	Autologous	Multiple Myeloma	Hematology	2022	Standard Therapy	Germany	33
1488	Apheresis	Allogeneic	Multiple Myeloma – Relapse	Hematology	2022	Standard Therapy	Germany	43
1489	Apheresis	Autologous	Multiple Myeloma Angioimmunoblastic T-Cell Lymphoma	Hematology	2022	Standard Therapy	Germany	62
1490	Apheresis	Allogeneic	Mycosis Fungoides	Hematology	2022	Standard Therapy	Poland	64
1491	Apheresis	Allogeneic	Myelodysplastic Syndrome	Hematology	2022	Standard Therapy	Poland	65
1492	Apheresis	Allogeneic	Myelodysplastic Syndrome	Hematology	2022	Standard Therapy	Poland	69
1493	Apheresis	Allogeneic	Myelodysplastic Syndrome	Hematology	2022	Standard Therapy	Poland	76
1494	Apheresis	Allogeneic	Myelodysplastic Syndrome	Hematology	2022	Standard Therapy	Poland	45
1495	Apheresis	Allogeneic	Myelodysplastic Syndrome	Hematology	2022	Standard Therapy	Poland	63
1496	Apheresis	Allogeneic	Myelodysplastic Syndrome	Hematology	2022	Standard Therapy	Poland	72
1497	Apheresis	Allogeneic	Myelodysplastic Syndrome	Hematology	2022	Standard Therapy	Poland	70
1498	Apheresis	Allogeneic	Myelodysplastic Syndrome	Hematology	2022	Standard Therapy	Poland	45
1499	Apheresis	Allogeneic	Myelodysplastic Syndrome	Hematology	2022	Standard Therapy	Poland	73
1500	Apheresis	Allogeneic	Myelodysplastic Syndrome	Hematology	2022	Standard Therapy	Poland	21

Previous

Page 15 of 72 1 13 14 15 16 17 72

Next